Cumulatively, these data demonstrate that IRX4204 treatment is effective at preventing and reversing cGVHD with BO as measured by PFTs, lung and liver pathology scores, and Tfr/Tfh imbalance associated with diminution of the GC immune responses. Here, TFRC is linked to bronchiolitis obliterans syndrome.